These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

180 related articles for article (PubMed ID: 39247184)

  • 1. Efficacy and safety of different regimens of neoadjuvant therapy in patients with hormone receptor-positive, her2-negative breast cancer: a network meta-analysis.
    Wu Y; Huang S; Wei Y; Huang M; Li C; Liang W; Qin T
    Front Immunol; 2024; 15():1420214. PubMed ID: 39247184
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Efficacy and safety of neoadjuvant therapy for HR-positive/HER2-negative early breast cancer: a Bayesian network meta-analysis.
    Chen R; Yu Y; Zhang J; Song C; Wang C
    Expert Rev Anticancer Ther; 2024 Jul; 24(7):599-611. PubMed ID: 38693054
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Efficacy and safety of immune checkpoint inhibitors as neoadjuvant therapy in perioperative patients with non-small cell lung cancer: a network meta-analysis and systematic review based on randomized controlled trials.
    Chen K; Wang X; Yue R; Chen W; Zhu D; Cui S; Zhang X; Jin Z; Xiao T
    Front Immunol; 2024; 15():1432813. PubMed ID: 39416776
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Endocrine treatment versus chemotherapy in postmenopausal women with hormone receptor-positive, HER2-negative, metastatic breast cancer: a systematic review and network meta-analysis.
    Giuliano M; Schettini F; Rognoni C; Milani M; Jerusalem G; Bachelot T; De Laurentiis M; Thomas G; De Placido P; Arpino G; De Placido S; Cristofanilli M; Giordano A; Puglisi F; Pistilli B; Prat A; Del Mastro L; Venturini S; Generali D
    Lancet Oncol; 2019 Oct; 20(10):1360-1369. PubMed ID: 31494037
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Landscape of neoadjuvant therapy in HER2-positive breast cancer: a systematic review and network meta-analysis.
    Villacampa G; Matikas A; Oliveira M; Prat A; Pascual T; Papakonstantinou A
    Eur J Cancer; 2023 Sep; 190():112885. PubMed ID: 37142539
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Capecitabine for hormone receptor-positive versus hormone receptor-negative breast cancer.
    Hoon SN; Lau PK; White AM; Bulsara MK; Banks PD; Redfern AD
    Cochrane Database Syst Rev; 2021 May; 5(5):CD011220. PubMed ID: 34037241
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Systematic review and network meta-analysis comparing palbociclib with chemotherapy agents for the treatment of postmenopausal women with HR-positive and HER2-negative advanced/metastatic breast cancer.
    Wilson FR; Varu A; Mitra D; Cameron C; Iyer S
    Breast Cancer Res Treat; 2017 Nov; 166(1):167-177. PubMed ID: 28752187
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Concurrent epirubicin and trastuzumab use increases complete pathological response rate without additional cardiotoxicity in patients with human epidermal growth factor receptor 2-positive early breast cancer: A meta-regression analysis.
    Yang MH; Huang CS; Chang DY; Hu FC; Huang SM; Huang PH; Chen IC; Chen TW; Lin CH; Lu YS
    Cancer Med; 2024 Jul; 13(14):e70005. PubMed ID: 39046067
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Efficacy of neoadjuvant chemotherapy combined with bevacizumab versus neoadjuvant chemotherapy alone for Her2-negative breast cancer: a meta-analysis of randomized controlled clinical trials].
    Han R; Wang G; Zhang Y; Zhao X
    Zhejiang Da Xue Xue Bao Yi Xue Ban; 2016 May; 45(4):379-386. PubMed ID: 27868411
    [TBL] [Abstract][Full Text] [Related]  

  • 10. HER2 and response to anthracycline-based neoadjuvant chemotherapy in breast cancer.
    Yao L; Liu Y; Li Z; Ouyang T; Li J; Wang T; Fan Z; Fan T; Lin B; Xie Y
    Ann Oncol; 2011 Jun; 22(6):1326-1331. PubMed ID: 21196440
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Retrospective analysis of neoadjuvant chemotherapy for breast cancer in Turkish patients.
    Duman BB; Afşar ÇU; Günaldi M; Sahin B; Kara IO; Erkisi M; Erçolak V
    Asian Pac J Cancer Prev; 2012; 13(8):4119-23. PubMed ID: 23098527
    [TBL] [Abstract][Full Text] [Related]  

  • 12. CDK4/6 Inhibitors in Combination With Hormone Therapy for HR
    Deng Y; Ma G; Li W; Wang T; Zhao Y; Wu Q
    Clin Breast Cancer; 2018 Oct; 18(5):e943-e953. PubMed ID: 29804650
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Neoadjuvant chemotherapy combined with endocrine therapy for hormone receptor-positive breast cancer: A systematic review and meta-analysis.
    Ma HF; Shen J; Xu B; Shen JG
    Medicine (Baltimore); 2023 Nov; 102(46):e35928. PubMed ID: 37986364
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Phase II trial of eribulin in patients who do not achieve pathologic complete response (pCR) following neoadjuvant chemotherapy.
    Yardley DA; Peacock N; Daniel B; Anz B; Molthrop DC; Shroff SK; Young R; Jankov A; Vander Woude A; Shastry M; Pasek J; DeBusk LM; Hainsworth JD
    Breast Cancer Res Treat; 2020 Apr; 180(3):647-655. PubMed ID: 32060783
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Platinum dose in neoadjuvant therapy for triple-negative breast cancer: A systematic review and network meta-analysis.
    Petrelli F; Ghidini A; Rea C; Parati MC; Borgonovo K; Ghidini M; Ruatta F; Zaniboni A; Luciani A; Garrone O; Tomasello G
    Curr Probl Cancer; 2024 Jun; 50():101096. PubMed ID: 38608530
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Trastuzumab-containing regimens for metastatic breast cancer.
    Balduzzi S; Mantarro S; Guarneri V; Tagliabue L; Pistotti V; Moja L; D'Amico R
    Cochrane Database Syst Rev; 2014 Jun; 2014(6):CD006242. PubMed ID: 24919460
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cyclin-dependent kinase 4 and 6 inhibitors in hormone receptor-positive, human epidermal growth factor receptor-2 negative advanced breast cancer: a meta-analysis of randomized clinical trials.
    Li J; Fu F; Yu L; Huang M; Lin Y; Mei Q; Lv J; Wang C
    Breast Cancer Res Treat; 2020 Feb; 180(1):21-32. PubMed ID: 31970560
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Long-term survival after neoadjuvant therapy for triple-negative breast cancer under different treatment regimens: a systematic review and network meta-analysis.
    Liu Z; Li J; Zhao F; Ren D; Li Z; Chen Y; Huang S; Liu Z; Zhao Y; Wang M; Li H; Xu Z; Shen G; Zhao J
    BMC Cancer; 2024 Apr; 24(1):440. PubMed ID: 38594636
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Identification of biology-based breast cancer types with distinct predictive and prognostic features: role of steroid hormone and HER2 receptor expression in patients treated with neoadjuvant anthracycline/taxane-based chemotherapy.
    Darb-Esfahani S; Loibl S; Müller BM; Roller M; Denkert C; Komor M; Schlüns K; Blohmer JU; Budczies J; Gerber B; Noske A; du Bois A; Weichert W; Jackisch C; Dietel M; Richter K; Kaufmann M; von Minckwitz G
    Breast Cancer Res; 2009; 11(5):R69. PubMed ID: 19758440
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Neoadjuvant Bevacizumab plus Chemotherapy versus Chemotherapy Alone to Treat Non-Metastatic Breast Cancer: A Meta-Analysis of Randomised Controlled Trials.
    Cao L; Yao GY; Liu MF; Chen LJ; Hu XL; Ye CS
    PLoS One; 2015; 10(12):e0145442. PubMed ID: 26717149
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.